Celcuity Expands Phase 3 Trial for Gedatolisib to Include Endocrine-Sensitive Breast Cancer Patients
Event summary
- Celcuity's Phase 3 VIKTORIA-2 trial for gedatolisib now includes endocrine-sensitive HR+/HER2- advanced breast cancer patients, expanding from its original focus on endocrine-resistant patients.
- The trial will enroll approximately 440 endocrine-resistant patients and 740 endocrine-sensitive patients, randomized to different treatment arms.
- Gedatolisib's NDA has been granted Priority Review by the FDA with a PDUFA goal date of July 17, 2026.
- Celcuity submitted a patent application for a subcutaneous formulation of gedatolisib to support long-term treatment.
The big picture
Celcuity's expansion of the VIKTORIA-2 trial reflects a strategic shift to broaden gedatolisib's potential patient population, addressing both endocrine-resistant and endocrine-sensitive HR+/HER2- advanced breast cancer. This move aligns with the industry trend of developing more comprehensive treatment options for heterogeneous cancer subtypes. The FDA's Priority Review designation underscores the unmet medical need in this space and the potential for gedatolisib to become a standard-of-care therapy.
What we're watching
- Clinical Efficacy
- Whether gedatolisib's combination therapy will demonstrate superior progression-free and overall survival rates compared to standard-of-care regimens in both endocrine-resistant and endocrine-sensitive cohorts.
- Regulatory Approval
- The pace at which the FDA will review and potentially approve gedatolisib, given the Priority Review status and the July 2026 PDUFA goal date.
- Market Adoption
- How the subcutaneous formulation of gedatolisib will impact patient compliance and long-term treatment adherence, potentially expanding its market potential.
Related topics